PARIS–(BUSINESS WIRE)–Regulatory News:

Hospitex, the Italian leader in the production of medical devices and a subsidiary of ALIKO SCIENTIFIC (Ikonisys SA) ( Euronext (EPA:) Growth Paris: ALIKO), today announced that it has obtained a public tender for “Gaetano Martino” University Hospital Located in Messina in Italy.

The contract, valued at € 668 thousand over three years, includes an option to extend it for two additional years, bringing the total potential value to €1.025 million. The tender covers the supply of alcohol for medical and hospital use, an important component for maintaining high standards in healthcare services.

Hospitex is accredited as a fiscal warehouse for alcohol by the Italian Customs Agency, a distinction that is one of the most challenging to obtain due to the complex regulatory, logistical, infrastructure, and administrative requirements. This accreditation demonstrates Hospitex’s operational excellence and positions the company as a reliable supplier capable of operating in highly complex regulated environments.

The company’s expertise in hydroalcoholic solutions and pure alcohol production goes beyond Italy, as Hospitex serves healthcare institutions throughout Europe, highlighting its capacity to deliver reliable, high quality medical alcohol solutions in a wide range.

Francesco Trisolini, CEO of Hospitexsays: “Securing this tender reaffirms our leadership in the healthcare sector and our ability to navigate the complexities of regulatory and logistical frameworks. Our fiscal warehouse accreditation highlights our operational excellence and demonstrates our willingness to respond to the needs of domestic and international clients. We are proud to partner with Gaetano Martino University Hospital and remain committed to delivering critical supplies that support health care efficiency.”

This success strengthens ALIKO SCIENTIFIC’s strategic position in the healthcare and life sciences sector, supporting its growth goals and commitment to innovation.

About ALIKO SCIENTIFIC (Ikonisys SA)

Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to the development of oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC’s mission is to revolutionize cancer diagnosis by combining advanced technologies, resources, and strategic investments to create a global center of excellence in oncology.

For more information, visit: www.alikoscientific.com

About IKONISYS

Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Using advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched accuracy, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as a pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes.

For more information, visit: www.ikonisys.com

About HOSPITEX

Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research, development, and production, thus ensuring the highest quality standards. Hospitex offers the world’s most advanced Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unparalleled precision. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cytology diagnostics.

For more information, visit: www.hospitex.com

Disclaimer

This press release contains forward-looking statements about the Company’s prospects and developments. These statements are sometimes distinguished by the use of the future tense, the conditional tense and forward-looking words such as “believe”, “intend”, “anticipate”, “plan”, “estimate”, “believe” , “must”, “may”, “want” or “will” or, where appropriate, the negative of these terms or any similar variants or expressions. This information is not historical data and should not be considered as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates deemed reasonable by the Company. This may change or change due to uncertainty related to the economic, financial, competitive and regulatory environment. This information contains data related to the Company’s intentions, estimates and goals regarding, in particular, the market, strategy, growth, results, financial condition and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not intend to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent on which the materialization of any risk or combination of risks. This may cause results to differ materially from those expressed in any forward-looking information, given that none of this forward-looking information constitutes a guarantee of actual results.

See the original version on businesswire.com: https://www.businesswire.com/news/home/20250114677393/en/

Iconisys
Alessandro Mauri
CFO
[email protected]

NewCap
Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations
[email protected]
Tel.: +33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
[email protected]
Tel.: +33 (0)1 44 71 94 98

Source: Ikonisys